2 résultats
First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study
Auteurs / Authors
Cortot AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, Charpentier S, Denis MG, Cadranel J.
Journal / Conference
Clinical Cancer Research
Année / Year
2021
PMID / session
Etude IFCT
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)
Auteurs / Authors
Cortot A B, Madroszyk A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Raimbourg J, Hureaux J, Moreau L, Debieuvre D, Morel H, Denis M, Amour E, Morin F, Moro-Sibilot D, Cadranel J
Journal / Conference
ASCO
Année / Year
2019
PMID / session
Poster
Etude IFCT